Evaluating the Efficacy of Brensocatib in Non-cystic Fibrosis Bronchiectasis

Bronchiectasis is a widely recognised chronic respiratory illness classified in severity by frequency of exacerbations within the past year, percent predicted forced expiratory volume in 1 second (%FEV1), previous hospital admissions and radiological severity, among other factors.The physiological process is understood to be driven by neutrophilic inflammation and subsequent bronchial wall destruction and dilatation.Brensocatib has emerged as a novel adjunct in the management of chronic bronchiectasis as a dipeptidyl peptidase-1 inhibitor, directly targeting the inflammatory process.The editorial aims to review the mechanism of action of brensocatib, current literature surrounding its efficacy and side effect profile, and potential implications of a wider rollout of the medication to the adult UK population.Whilst the current literature does support a modest reduction in the frequency of exacerbations for patients who trialled bresnocatib, there is a large amount of uncertainty regarding long-term safety, implementation into the current regime, and cost-effectiveness.